A study by Scripps Research and eMed digital medicine reveals a remarkably high percentage of COVID-19 rebound cases in both neglected people and those treated with Paxlovid.
Preliminary arise from a Scripps Research and eMed digital medicine study reveal a suddenly high proportion of COVID-19 rebound cases in neglected people, in addition to those treated with Paxlovid.
” COVID rebound,” in which evidence of the disease vanishes and then returns days or weeks later on, is remarkably common– whether or not patients are given the antiviral Paxlovid.
The outcomes, reported just recently in the journal Clinical Infectious Diseases by researchers at Scripps Research and the digital health business eMed, are a preliminary readout from a continuous observational research study of people who order SARS-CoV-2 antigen test kits online. The researchers found that in an initial group of 170 eMed Test-to-Treat ™ package users, the disappearance and then return of evidence of the virus on antigen tests and in self-reported COVID-19 symptoms occurred in 9.3% and 7.0% of patients who opted not to take antiviral treatment, and in 14.2% and 18.9% of those who selected Paxlovid.
Although a higher proportion of the Paxlovid-treated group reported COVID-19 rebound, the difference was not statistically considerable in this early picture of the continuous research study, which is designed ultimately to register an overall of 800 patients.
” These preliminary outcomes recommend that rebound after clearance of SARS-CoV-2 test positivity or COVID-19 sign resolution is more common than previously reported in both dealt with and untreated patients,” states study lead author Jay Pandit, MD, an assistant teacher and director of Digital Medicine at the Scripps Research Translational Institute. “Were going to require a larger set of individuals and more extended follow-up to better understand this rebound phenomenon.”
The study, performed from August to November of in 2015, was a collaboration with eMed, consisting of epidemiologist and Chief Science Officer Michael Mina, MD, PhD, formerly teacher at Harvard T.H. Chan School of Public Health, and others at the Test-to-Treat company, which is also carrying out the NIH Home Test to Treat COVID-19 program.
Reports of COVID-19 rebound started appearing in the medical literature in 2022. The cause of rebound has actually been uncertain, although the idea in the majority of these reports has been that rebound happens more often in clients treated with Paxlovid. The latter, a mix of 2 antiviral compounds (nirmatrelvir and ritonavir), received emergency situation use approval in late 2021 from the U.S. Food and Drug Administration (FDA) for treating clients who have mild-to-moderate COVID-19 and are at high risk of establishing severe COVID-19.
To assist light up the rebound phenomenon and any connection to Paxlovid, Pandit and his coworkers teamed up with eMed to drive a “real-world” research study of results among people utilizing the businesss COVID-19 Test-to-Treat antigen test sets with telehealth proctoring and telemedicine.
” As the COVID-19 landscape continues to progress, the significance of making efficient and prompt treatments available and therefore helping in reducing serious illness outcomes can not be overemphasized,” Mina states. “Collaborations such as this with the Scripps Research Translation Institute are a key part of efforts to collect evidence-based data and respond to critical questions connected with treatment outcomes. We are likewise happy that this study not just uses new data surrounding COVID-19 healing and treatment results, however likewise highlights the advantages of industry and academic partnerships to accelerate premium public health and translational research study.”
The group then compared the rates of rebound for those who did and didnt choose to take Paxlovid. Rebound was determined in two ways: a favorable test outcome after an unfavorable test, or a reported recurrence of symptoms after symptom resolution.
Either method rebounds were measured, the Paxlovid group experienced them at a greater rate: 14.2% vs. 9.3% for antigen test rebounds, and 18.9% vs. 7.0% for sign rebounds. Age, gender and pre-existing conditions also did not appear to influence rebound.
Pandit stresses that the research study is not currently powered to detect statistically considerable outcomes, and a last analysis should include up to 800 individuals and hence need to have much more power to create definitive findings. He includes, the preliminary findings already make clear that the rebound rates for both dealt with and neglected groups are higher than the rates reported in prior studies. An analysis of their medical trial results by Pfizer, the maker of Paxlovid, discovered rebound rates of just about 2% in both Paxlovid and placebo groups over a two-week period.
In addition to increasing the number of individuals in their continuous study, Pandit and colleagues prepare to start sequencing the infection discovered in individuals and screening individuals blood samples for antibody levels and other immune markers.
” Were hoping to answer key concerns about the rebound phenomenon, such as whether its improved by Paxlovid, how much it depends upon the viral variant and what is the role of the patients body immune system,” Pandit says.
He and his team likewise plan to enhance the balance of racial and ethnic representation in between the treatment and control groups: In the preliminary group of 170, Whites were a lot more most likely than Blacks and Latinos to go with Paxlovid treatment.
Reference: “The COVID-19 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated with Nirmatrelvir Plus Ritonavir Versus Untreated Controls” by Jay A Pandit, Jennifer M Radin, Danielle Chiang, Emily G Spencer, Jeff B Pawelek, Mira Diwan, Leila Roumani and Michael J Mina, 22 February 2023, Clinical Infectious Diseases.DOI: 10.1093/ cid/ciad102.
Assistance for the study was provided by eMed, the National Institute of Allergy and Infectious Diseases (3U01AI151812-03S2), and the National Center for Advancing Translational Sciences (NCATS UL1 TR002550).
Reports of COVID-19 rebound started appearing in the medical literature in 2022. The cause of rebound has actually been unclear, although the recommendation in many of these reports has been that rebound takes place more often in clients treated with Paxlovid. Either way rebounds were determined, the Paxlovid group experienced them at a higher rate: 14.2% vs. 9.3% for antigen test rebounds, and 18.9% vs. 7.0% for symptom rebounds. He adds, the preliminary findings already make clear that the rebound rates for both treated and unattended groups are higher than the rates reported in previous research studies. An analysis of their medical trial outcomes by Pfizer, the maker of Paxlovid, found rebound rates of just about 2% in both Paxlovid and placebo groups over a two-week period.
